Home » Stocks » Seres Therapeutics

Seres Therapeutics, Inc. (MCRB)

Stock Price: $28.57 USD 5.01 (21.26%)
Updated Aug 13, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.18B
Revenue (ttm) 28.89M
Net Income (ttm) -75.78M
Shares Out 76.26M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $28.57
Previous Close $23.56
Change ($) 5.01
Change (%) 21.26%
Day's Open 24.37
Day's Range 24.25 - 31.18
Day's Volume 17,803,097
52-Week Range 2.52 - 33.00

More Stats

Market Cap 2.18B
Enterprise Value 2.16B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 76.26M
Float 47.26M
EPS (basic) -1.04
EPS (diluted) -1.07
FCF / Share -1.13
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.44M
Short Ratio 9.57
Short % of Float 23.03%
Beta 1.02
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 75.42
PB Ratio n/a
Revenue 28.89M
Operating Income -76.61M
Net Income -75.78M
Free Cash Flow -82.81M
Net Cash 21.11M
Net Cash / Share 0.28
Gross Margin -157.98%
Operating Margin -265.21%
Profit Margin -262.30%
FCF Margin -286.67%
ROA -38.81%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$32.42*
(13.48% upside)
Low
24.0
Current: $28.57
High
41.0
Target: 32.42
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue34.5128.2732.1021.77----
Revenue Growth22.07%-11.94%47.48%-----
Gross Profit34.5128.2732.1021.77----
Operating Income-71.88-100-91.40-92.84-54.86-15.08-6.05-3.03
Net Income-70.28-98.94-89.38-91.58-54.78-16.71-6.10-3.13
Shares Outstanding56.6540.7440.4539.8523.536.756.395.73
Earnings Per Share-1.24-2.43-2.21-2.30-2.33-2.67-1.09-0.59
Operating Cash Flow-76.52-62.85-75.5243.92-40.84-10.36-5.32-2.93
Capital Expenditures-1.00-1.94-4.68-21.49-4.36-1.00-0.17-0.29
Free Cash Flow-77.52-64.79-80.2022.43-45.21-11.36-5.50-3.22
Cash & Equivalents94.8285.931501952071141.690.00
Total Debt44.78----2.500.84-
Net Cash / Debt50.0485.931501952071120.850.00
Assets1321201902732171172.13-
Liabilities18116912914011.517.991.66-
Book Value-48.32-48.0560.70133205-26.72-11.12-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Seres Therapeutics, Inc.
Country United States
Employees 108
CEO Eric D. Shaff

Stock Information

Ticker Symbol MCRB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MCRB
IPO Date June 26, 2015

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.